Literature DB >> 1749303

5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures.

F Franchi1, C Barone, P Seminara, G Codacci-Pisanelli, M Codacci-Pisanelli, G M Ferri, C Garufi, A Grieco, V Pagani.   

Abstract

Eighty-seven colorectal adenocarcinomas from untreated patients were investigated by short term tumor cultures to test in vitro sensitivity to 5-fluorouracil and mitomycin C. This study reports the preliminary results of a multistep program aimed at the prospective clinical application of the assay. At present this in vitro experience was performed in parallel with a clinical trial carried out with the same drugs. The in vitro activity of the two anticancer agents is in agreement with the response rate reported in monochemotherapy; our data would suggest an increase of responses using the combination of fluorouracil and mitomycin in comparison to single drug therapy. A low cosensitivity rate and a high number of cases sensitive to one drug but resistant to the other, account for the use of this test as screening of active drugs in the individual patient.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749303     DOI: 10.1007/bf02988857

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  10 in total

Review 1.  Chemotherapy of gastrointestinal cancer.

Authors:  C G Moertel
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

2.  Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.

Authors:  S Krauss; T Sonoda; A Solomon
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

3.  Determination of therapeutic index of drugs by in vitro sensitivity tests using human host and tumor cell suspensions.

Authors:  G Tisman; V Herbert; H Edlis
Journal:  Cancer Chemother Rep       Date:  1973-02

Review 4.  Current protocol approaches in large bowel cancer.

Authors:  S K Carter
Journal:  Semin Oncol       Date:  1976-12       Impact factor: 4.929

5.  Application of an in vitro antimetabolic assay to human germ cell testicular tumors for the preclinical evaluation of drug sensitivity.

Authors:  O Sanfilippo; R Silvestrini; N Zaffaroni; L Piva; G Pizzocaro
Journal:  Cancer       Date:  1986-10-01       Impact factor: 6.860

6.  5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.

Authors:  T Buroker; P N Kim; C Groppe; J McCracken; R O'Bryan; F Panettiere; C Coltman; R Bottomley; H Wilson; J Bonnet; T Thigpen; V K Vaitkevicius; B Hoogstraten; L Heilbrun
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

7.  Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas.

Authors:  T R Buroker; P N Kim; L H Baker; V Ratanatharathron; B Wojtaszak; V K Vaitkevicius
Journal:  Med Pediatr Oncol       Date:  1978

8.  Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.

Authors:  K A Kennedy; S Rockwell; A C Sartorelli
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

9.  Reliability of an in vitro short-term assay to predict the drug sensitivity of human breast cancer.

Authors:  M G Daidone; R Silvestrini; O Sanfilippo; N Zaffaroni; M Varini; M De Lena
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

10.  5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity.

Authors:  F Franchi; C Barone; E Ricevuto; A Cassano; A Astone; C Pozzo; L Sofo; G Netri; C Ratto; C Coco
Journal:  Med Oncol Tumor Pharmacother       Date:  1991
  10 in total
  4 in total

1.  Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.

Authors:  Hairong Cheng; Bo Hong; Lanlan Zhou; Joshua E Allen; Guihua Tai; Robin Humphreys; David T Dicker; Yingqiu Y Liu; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

2.  5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity.

Authors:  F Franchi; C Barone; E Ricevuto; A Cassano; A Astone; C Pozzo; L Sofo; G Netri; C Ratto; C Coco
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

3.  Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells.

Authors:  Seog-Young Kim; Dae-Hee Lee; Xinxin Song; David L Bartlett; Yong Tae Kwon; Yong J Lee
Journal:  Apoptosis       Date:  2014-11       Impact factor: 4.677

4.  Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.

Authors:  Angélique Saint; Ludovic Evesque; Alexander T Falk; Gérard Cavaglione; Lucile Montagne; Karen Benezery; Eric Francois
Journal:  Cancer Med       Date:  2019-09-16       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.